Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thank you
PharmaCyte is a pioneer. Here is similar technology. https://newatlas.com/medical/drug-factory-beads-tumors-cancer-week/
Unfortunately the end of Q1 is in the summer. Their fiscal year begins May 1st.
I’m good. That is the problem with texts, you can’t tell mood or intent. I guess that is what emojis are for but they are a poor substitute for face to face conversation with all the subtle body language and tone of voice. Good luck to you.
The comment I made was regarding the 1 year inactive status for an IND on hold.
FDA says: An inactive application may be re-activated if activities under the IND application have restarted.
Checking off list of requirements are steps to get to restarting IND. Therefore inactive status is irrelevant as they can reactivate application when they complete the list.
They are checking off items on the list. Your assumption that it is a scam is an opinion. Given all we have been through, it is an understandable one but still, an opinion. I see some progress so I am willing to wait and see. I am not investing any more than what I have in to it, and wanting to see it crash and burn isn’t productive. They have the cash to get it done. We are seeing light from the covid crisis and the gears of the economy are getting some attention. I believe better days are ahead, but I have been wrong before.
Please. That means nothing. They can submit the required material and activate it again.
12+… but who’s counting. Should get news soon. A year to work on list. They should have made significant progress now, especially with infusion of money.
These doctors and scientists know what this drug can do. They are experts in their field. I am all for them to have the chance to prove the technology. Let’s get this to the trials.
Yes but it will be more concentrated at the point and time it is released into the blood stream ( just upstream from tumor and the Cell In A Box activators) then it will get diluted in the blood stream as it goes to the rest of the body. They can use less chemo drug because they are not trying to get the full body up to effective levels that it achieved in the localized dose.
KW predicted by the end of the year they would be done with the list. We shall see.
Nope. Different test.
The latest news about not altering the DNA that is.
Wonder if this was the pig test mentioned in the FDA list. If so, that is significant.
PharmaCyte owns the rights to this delivery system (“cotton” capsules) for cancer and diabetes. Imagine owning the rights to syringe needles for cancer and diabetes! It’s a big market.
As far as competent companies go, many have “conflicts of interest” that put their new technology development on the back burner. Kodak invented the digital camera in the mid 1970’s, yet they shelved it because of their cash cow, film and film development. They lost out big once the digital camera revolution got it’s start.
One other thing, the “cotton capsule” keeps the cells and the patient protected. My guess is that the immune system would destroy the contents quickly if exposed. The tests are showing the capsules are up to the tasks and hold up well.
Nothing is guaranteed but it would be a shame not to properly test this technology. We would have actual data to condemn or praise it instead of all these speculative opinions. The old saying that ends with “Everyone has one” is true.
There is rarely one path to fight cancer. Options are desirable. Some patients don’t qualify for immunotherapy due to unique circumstances. Let’s get this treatment through trials and prove it’s merits or not.
The FDA knows PharmaCyte and gave them a list of tasks to do before resubmitting IND and starting phase 2B trials. They are fine with them doing that. The list didn’t include starting over which seems to be what you are suggesting.
And McDonald’s still sells hamburgers. Nothing new but what they had is still relevant and with PharmaCyte’s working capital the become very interesting assets.
That is a fair argument. I have no knowledge of exactly what was on the list or how long each additional test should take. Waggoner did say it would be done by the end of this year. And he did get big investor buy in after making that statement and moving to Nasdaq. They have the money to move forward. I am in a wait and see holding pattern.
Sorry, that’s not the way it works. They can resubmit after addressing the list of issues. They have the cash to do that and pay for trials. Full speed ahead!
Austrianova got $100 million a couple weeks ago to go public, and now PharmaCyte has $90 million. Good money coming to this technology. Should see some real developments soon
We have a more powerful investor to please. I think PRs will be regular now that they have a budget. News should be coming soon too.
I doubt it. After getting this into fully funded trials, the remainder of the 60 to 80M could help ramp up the diabetes cure, and additional cancer studies… BIG money once they prove the CIAB technology works.
It was over the break even point last February. Given a little good news, it should be there again. The last 6 months have taken a toll but it is temporary. They have their money and are on Nasdaq. When IND is approved this will easily be in the hundreds. Successful trials could push it to $1000. Buyout for technology multiple thousands. Forty bucks in short term should be a no brainer.
Just over $40 to break even for me. Averaging down for maybe 6 or 7 years.
We have the FDA list to get IND approved. Then off to trials
Trials will show one way or the other. Let’s get there and see.
It’s still a disruptive technology that some want to stop
And have the funds for a proper PR/news push to get the word out!!!
So when it got to 60 cents it would have been trading at $1000?
Step by step, getting to IND. Knocking items off the list.
Pig test and other things on the list cost money.
You need to understand percentages. Your percentage of the company didn’t change because of the split. The issuing of stock will change it, but not the split itself.
The thing that gives me hope is we are in the big leagues now, according to plan. Deep pockets are looking for innovative technology to invest in, so the company has to get its story out there. We should also hear about behind the scenes partner development or mergers if they are in the works. Lots of things in motion so hold on tight. The price should climb pretty dramatically ($150 to $300 per share?) in short order if they follow through. Long term in the thousands? Hopeful
PharmaCyte is slow but persistent at checking off their “to do” list. If they have set their minds to being listed, I believe they will succeed. Be ready. They have a plan.
In 2018 it got over $200 per share (adjusted). In 2014 it got to $500 a share (adjusted).
Good news will move this stock.
In March it got up to $50 per share (adjusted)
Alright, didn’t like the last post. I’ll try to put it another way.
PharmaCyte has disruptive technology and some are not happy. The little pharma is close to a breakthrough so watch out.
Better?